



## PRESS RELEASE

April 25, 2022

# ZICCUM AB sharpens focus on three key vaccine platforms

**In a strategic sharpening of its focus Ziccum AB is targeting three key vaccine platforms in its research and development work through 2022 and 2023 – driven by input from external collaborations and new internal technology capabilities. Ziccum Chairman Fredrik Sjövall: “a reviewed strategy based on these key, high-potential platforms bring a new focus to our work and value creation.”**

With new CEO Ann Gidner beginning her role on May 9 and the company expanded into larger premises in April, Ziccum is now focusing on three key vaccine platforms in parallel with a streamlined project program.

Chairman Fredrik Sjövall: “This strategy will focus and drive forward business development and significantly strengthen the company’s offering to industrial partners. It will also serve as a foundation for generating new patents – not least in the area of mRNA/LNP (Liquid Nanoparticles).”

### GENERATING NEW ROBUST DATA: A TOP PRIORITY

Ziccum has achieved positive preliminary data in tests with individual materials across several different vaccine platforms, [as reported in December](#). Now however the company is focusing on gathering further data from a select target group of three key platforms:

**Viral Vector platform using Adenovirus.** Four major Covid-19 vaccines already use adenovirus vaccine vectors as a platform. The platform enables efficient gene transduction and research is ongoing in a wide range of indications, including in major projects in Sweden and the Nordics. Ziccum has worked extensively with adenovirus and in January 2019 [submitted a patent application for a temperature-stable, dry formulation of Adenovirus](#).

**Subunit vaccine (adjuvanted) platform:** This platform is also being used in major Covid-19 vaccine candidates. Instead of using the whole pathogen, protein-based adjuvant vaccines use a defined protein antigen from the pathogen which can be recognized by the body’s immune system to provoke an immune response. Protein-based vaccines have been successfully developed over recent decades to treat diseases from diphtheria to tetanus. Ziccum is working on this platform in collaboration with a major research institute in vaccination in the Nordic region.

**mRNA/LNP vaccine platform:** Generating data on dry-formulated mRNA/LNP materials is a key strategic priority for Ziccum, as stated in the [3 March 2022 update](#). Covid-19 has highlighted the efficacy of mRNA/LNP as a vaccine platform enormously. Ziccum is now expanding its in-house capabilities and has recently made major investments in new facilities and specialized equipment for manufacturing and evaluating dry formulations of mRNA/LNP materials – investments which will be covered in an upcoming Press Release.

Chairman Fredrik Sjövall: "These investments will make us more independent in pursuing our own mRNA/LNP studies and intellectual property. Focusing in on select high-value projects with prestigious partners, plus our own in-house work on mRNA/LNP, will increase the value and range of data we can deliver to the industry. After years of working with diverse substances across a large number of platforms it brings new focus and impetus to our work and value creation."

**For more information about Ziccum, please contact:**

---

Fredrik Sjöval,  
Chairman of the Board, Ziccum AB  
Mail: [sjovall@ziccum.com](mailto:sjovall@ziccum.com)  
Mobile: +46 706 45 08 75

**Certified Adviser**

Erik Penser Bank AB  
Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)  
Phone: +46 8 463 83 00

**About Ziccum**

---

Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.

**Attachments**

---

[ZICCUM AB sharpens focus on three key vaccine platforms](#)